The Study
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review.
This study combines results from several fair-quality experiments where people were randomly given one of two cholesterol medicines. It shows that a lower-dose combo pill works about as well as a stronger single pill at lowering bad cholesterol, and both seem equally safe in the short term.
Analysis score
Maximum 100 for a systematic review with meta-analysis.
Where the score came from
Doctors wanted to know if taking two weaker cholesterol pills together works as well as one strong pill, and if it's safer.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 539 / 100
Quality score
The highest quality evidence. These studies systematically search, appraise, and synthesize results from multiple individual studies, providing the most reliable summary of current knowledge.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This means patients might get the same heart protection with a gentler pill combo that’s easier on the body.
- 2The two-pill combo lowered bad cholesterol just as much as the strong one-pill dose.
- 3It also lowered total cholesterol a bit more.
- 4Both had similar side effects.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Yonsei medical journal
Year
2024
Authors
Yura Kang, Jung Mi Park, Sang-Hak Lee
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.